Giuseppe MichieliAcquisition of specific #human respiratory tract binding of 2.3.4.4b #H5N1 #hemagglutinins requires multiple #mutations, https://etidiohnew.blogspot.com/2026/04/acquisition-of-specific-human.html
Stabilization of the trimeric pre-fusion structures of #influenza #H1 and #H9 #hemagglutinins by mutations in the stem helices, https://etidiohnew.blogspot.com/2025/08/stabilization-of-trimeric-pre-fusion.html
Memory T and B cells with recognition of avian #influenza #hemagglutinins are poorly responsive to existing seasonal influenza #vaccines, https://etidiohnew.blogspot.com/2025/04/memory-t-and-b-cells-with-recognition.html
Structure-based #Design of Chimeric #Influenza #Hemagglutinins to Elicit Cross-group #Immunity, https://etidiohnew.blogspot.com/2025/02/structure-based-design-of-chimeric.html
Structure-based #Design of #Chimeric #Influenza #Hemagglutinins to Elicit Cross-group #Immunity, https://etidiohnew.blogspot.com/2024/12/structure-based-design-of-chimeric.html
Fucosylated and non-fucosylated alpha2,3 #sialosides were detected on the #bovine #mammary #gland tissues, BioRxIV: https://www.biorxiv.org/content/10.1101/2024.07.29.605565v1
Receptors for high pathogenicity avian #influenza viruses (#HPAIVs) in mammary glands of dairy #cattle were detected using various recombinant #hemagglutinins (rHAs). Results demonstrated presence of fucosylated and non-fucosylated alpha2,3 sialosides, which were typically targeted by the HA of clade 2.3.4.4b HPAIVs.
Occurrence of Circulating #Antibodies vs #Hemagglutinins of #Influenza Viruses in the 2022/23 Epidemic Season in #Poland, Viruses: https://www.mdpi.com/1999-4915/16/7/1105
Test results have confirmed presence of anti-HA antibodies for #antigens A/Victoria/2570/2019 #H1N1pdm09, A/Darwin/9/2021 #H3N2, B/Austria/1359417/2021 (B/Yamagata lineage) & B/ Phuket/3073/2013 (B/Victoria lineage) present in influenza #vaccine recommended by WHO for 2022/23 epidemic season.
Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland
The aim of this study was to determine the level of anti-hemagglutinin antibodies in blood sera collected from patients during the 2022/2023 epidemic season in Poland. A total of 700 sera samples from patients across the country were tested. The samples were divided into seven groups according to the age of the patients, with 100 samples from each age group. The hemagglutination inhibition test (OZHA) was used to determine the level of anti-hemagglutinin antibodies. The test results have confirmed the presence of anti-hemagglutinin antibodies for antigens A/Victoria/2570/2019 (H1N1)pdm09, A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (B/Yamagata lineage) and B/ Phuket/3073/2013 (B/Victoria lineage) present in the influenza vaccine recommended by the World Health Organization (WHO) for the 2022/2023 epidemic season. The highest geometric mean antibody titres (GMT) and protection rate values (%) were recorded for hemagglutinin A/H3N2. In Poland, in the 2022/2023 epidemic season, the percentage of the population vaccinated against influenza was 5.7%. Therefore, the test results can be interpreted as the response of the immune system in patients who have been previously infected with an influenza virus.